{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:55:11Z","timestamp":1788897311456,"version":"build-2803163510"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00198-025-07798-2","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:22:18Z","timestamp":1768209738000},"page":"341-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?"],"prefix":"10.1007","volume":"37","author":[{"given":"G","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Biver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9165-1444","authenticated-orcid":false,"given":"J J","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-9301","authenticated-orcid":false,"given":"C","family":"Campusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cannata-And\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Confavreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T J","family":"de Villiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P R","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4787-3151","authenticated-orcid":false,"given":"P","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"El Maghraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1537-422X","authenticated-orcid":false,"given":"R","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"M L","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"7798_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","volume":"389","author":"O Ginsburg","year":"2017","unstructured":"Ginsburg O, Bray F, Coleman MP et al (2017) The global burden of women\u2019s cancers: a grand challenge in global health. Lancet 389:847\u2013860. https:\/\/doi.org\/10.1016\/S0140-6736(16)31392-7","journal-title":"Lancet"},{"key":"7798_CR2","unstructured":"American Cancer Society (2021) Hormone Therapy for Breast Cancer. Atlanta (GA). Available from:https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/treatment\/hormone-therapy-forbreast-cancer.html. Accessed 31 Oct 2023"},{"key":"7798_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076834","volume":"24","author":"L Clusan","year":"2023","unstructured":"Clusan L, Ferri\u00e8re F, Flouriot G, Pakdel F (2023) A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci 24:6834. https:\/\/doi.org\/10.3390\/ijms24076834","journal-title":"Int J Mol Sci"},{"key":"7798_CR4","doi-asserted-by":"publisher","first-page":"R337","DOI":"10.1530\/ERC-16-0121","volume":"23","author":"CG Murphy","year":"2016","unstructured":"Murphy CG, Dickler MN (2016) Endocrine resistance in hormone\u2010responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer 23:R337\u2013R352. https:\/\/doi.org\/10.1530\/ERC-16-0121","journal-title":"Endocr Relat Cancer"},{"key":"7798_CR5","first-page":"541","volume":"26","author":"RD Rao","year":"2012","unstructured":"Rao RD, Cobleigh MA (2012) Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park) 26:541\u2013547","journal-title":"Oncology (Williston Park)"},{"key":"7798_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-319-70197-4_2","volume":"173","author":"R Shah","year":"2018","unstructured":"Shah R, O\u2019Regan RM (2018) Adjuvant endocrine therapy. Cancer Treat Res 173:15\u201329. https:\/\/doi.org\/10.1007\/978-3-319-70197-4_2","journal-title":"Cancer Treat Res"},{"key":"7798_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ et al (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1\u201312. https:\/\/doi.org\/10.1016\/j.jbo.2017.03.001","journal-title":"J Bone Oncol"},{"key":"7798_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:1341\u20131352. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1","journal-title":"Lancet"},{"key":"7798_CR9","doi-asserted-by":"publisher","unstructured":"Winer EP, Hudis C, Burstein HJ et al (2005) American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report. J Clin Oncol 23: 619\u201329. https:\/\/doi.org\/10.1200\/JCO.2005.09.121","DOI":"10.1200\/JCO.2005.09.121"},{"key":"7798_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","volume":"23","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2022","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2022) Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 23:382\u2013392. https:\/\/doi.org\/10.1016\/S1470-2045(21)00758-0","journal-title":"Lancet Oncol"},{"key":"7798_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00223-015-0046-x","volume":"97","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Kim KM, Brown JK et al (2015) Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer. Calcif Tissue Int 97:551\u2013559. https:\/\/doi.org\/10.1007\/s00223-015-0046-x","journal-title":"Calcif Tissue Int"},{"key":"7798_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100254","volume":"18","author":"U Stumpf","year":"2019","unstructured":"Stumpf U, Kostev K, Kyvernitakis J et al (2019) Incidence of fractures in young women with breast cancer - a retrospective cohort study. J Bone Oncol 18:100254. https:\/\/doi.org\/10.1016\/j.jbo.2019.100254","journal-title":"J Bone Oncol"},{"key":"7798_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K, Lima Ferreira J, Tsourdi E et al (2021) Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 28:100355. https:\/\/doi.org\/10.1016\/j.jbo.2021.100355","journal-title":"J Bone Oncol"},{"key":"7798_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100252","volume":"18","author":"A Galvano","year":"2019","unstructured":"Galvano A, Scaturro D, Badalamenti G et al (2019) Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. J Bone Oncol 18:100252. https:\/\/doi.org\/10.1016\/j.jbo.2019.100252","journal-title":"J Bone Oncol"},{"key":"7798_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P et al (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 6:901\u2013910. https:\/\/doi.org\/10.1016\/S2213-8587(18)30047-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7798_CR16","doi-asserted-by":"publisher","unstructured":"Hadji P, Aapro M, Nasser Al-Dagri N et al (2025) Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: an updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol 53:100694. https:\/\/doi.org\/10.1016\/j.jbo.2025.100694","DOI":"10.1016\/j.jbo.2025.100694"},{"key":"7798_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Kees Stad R et al (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39:58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"key":"7798_CR18","doi-asserted-by":"crossref","unstructured":"Tsourdi E, Ominsky MS, Rachner TD et al (2020) Pharmacological mechanisms of therapeutics: receptor activator of nuclear factor\u2013kappa B ligand inhibition. In: Bilezikian JP, Martin TJ, Clemens TL, Rosen CJ, editors. Principles of bone biology. 4th ed. Academic 1689-710","DOI":"10.1016\/B978-0-12-814841-9.00073-7"},{"key":"7798_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(15)60995-3","journal-title":"Lancet"},{"key":"7798_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","volume":"20","author":"M Gnant","year":"2019","unstructured":"Gnant M, Pfeiler G, Steger GG et al (2019) Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:339\u2013351. https:\/\/doi.org\/10.1016\/S1470-2045(18)30862-3","journal-title":"Lancet Oncol"},{"key":"7798_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman R, Finkelstein DM, Barrios C et al (2020) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet 21:60\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(19)30687-4","journal-title":"Lancet"},{"key":"7798_CR22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH et al (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"key":"7798_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u201380. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"key":"7798_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229. https:\/\/doi.org\/10.1016\/j.bone.2008.04.007","journal-title":"Bone"},{"key":"7798_CR25","doi-asserted-by":"publisher","unstructured":"Cummings SR, Ferrari S, Richard Eastell et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","DOI":"10.1002\/jbmr.3337"},{"key":"7798_CR26","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M et al (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res 37:2112\u20132120. https:\/\/doi.org\/10.1002\/jbmr.4705","journal-title":"J Bone Miner Res"},{"key":"7798_CR27","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM et al (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 104:1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"key":"7798_CR28","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2017.14484","volume":"147","author":"C Meier","year":"2017","unstructured":"Meier C, Uebelhart B, Aubry-Rozier B et al (2017) Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO\/ASCO. Swiss Med Wkly 147:w14484. https:\/\/doi.org\/10.4414\/smw.2017.14484","journal-title":"Swiss Med Wkly"},{"key":"7798_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","volume":"179","author":"E Gonzalez-Rodriguez","year":"2020","unstructured":"Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D et al (2020) Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat 179:153\u2013159. https:\/\/doi.org\/10.1007\/s10549-019-05458-8","journal-title":"Breast Cancer Res Treat"},{"key":"7798_CR30","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab from clinic and biomechanics. Osteoporos Int 27:1917\u201321. https:\/\/doi.org\/10.1007\/s00198-015-3458-6","journal-title":"Osteoporos Int"},{"key":"7798_CR31","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA et al (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2- year clinical trial. J Bone Miner Res 34:2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Miner Res"},{"issue":"12","key":"7798_CR32","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200162","volume":"1","author":"M Gnant","year":"2022","unstructured":"Gnant M, Frantal S, Pfeiler G et al (2022) Long-term outcomes of adjuvant denosumab in breast cancer. NEJM Evid EVIDoa2200162. https:\/\/doi.org\/10.1056\/EVIDoa2200162","journal-title":"NEJM Evid"},{"key":"7798_CR33","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1200\/JCO.2012.44.7805","volume":"31","author":"PE Goss","year":"2013","unstructured":"Goss PE, Ingle JN, Pritchard KI et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 - a randomized controlled phase III trial. J Clin Oncol 31:1398\u2013404. https:\/\/doi.org\/10.1200\/JCO.2012.44.7805","journal-title":"J Clin Oncol"},{"key":"7798_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/BCTT.S29432","volume":"4","author":"M Bauer","year":"2012","unstructured":"Bauer M, Bryce J, Hadji P (2012) Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Med Press) 4:91\u2013101. https:\/\/doi.org\/10.2147\/BCTT.S29432","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"7798_CR35","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051\u20131057. https:\/\/doi.org\/10.1200\/JCO.2007.11.0726","journal-title":"J Clin Oncol"},{"key":"7798_CR36","doi-asserted-by":"publisher","unstructured":"Coleman RE, Banks LM, Hannon RA, et al (2008) Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. J Clin Oncol 26:587. https:\/\/doi.org\/10.1200\/jco.2008.26.15_suppl.587","DOI":"10.1200\/jco.2008.26.15_suppl.587"},{"key":"7798_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10549-024-07252-7","volume":"206","author":"C Blomqvist","year":"2024","unstructured":"Blomqvist C, Vehmanen L, Kellokumpu-Lehtinen PL et al (2024) Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study. Breast Cancer Res Treat 206:57\u201365. https:\/\/doi.org\/10.1007\/s10549-024-07252-7","journal-title":"Breast Cancer Res Treat"},{"key":"7798_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/GME.0000000000000515","volume":"23","author":"P Villa","year":"2016","unstructured":"Villa P, Lassandro AP, Amar ID et al (2016) Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer. Menopause 23:33\u201339. https:\/\/doi.org\/10.1097\/GME.0000000000000515","journal-title":"Menopause"},{"key":"7798_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bone.2017.01.013","volume":"97","author":"R Pedersini","year":"2017","unstructured":"Pedersini R, Monteverdi S, Mazziotti G et al (2017) Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study. Bone 97:147\u2013152. https:\/\/doi.org\/10.1016\/j.bone.2017.01.013","journal-title":"Bone"},{"key":"7798_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx141","author":"H Goldvaser","year":"2018","unstructured":"Goldvaser H, Barnes TA, \u0160eruga B et al (2018) Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx141","journal-title":"J Natl Cancer Inst"},{"key":"7798_CR41","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40618-019-01063-0","volume":"42","author":"A Catalano","year":"2019","unstructured":"Catalano A, Gaudio A, Agostino RM et al (2019) Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors. J Endocrinol Invest 42:1337\u20131343. https:\/\/doi.org\/10.1007\/s40618-019-01063-0","journal-title":"J Endocrinol Invest"},{"key":"7798_CR42","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00198-016-3899-6","volume":"28","author":"AR Hong","year":"2017","unstructured":"Hong AR, Kim JH, Lee KH et al (2017) Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. Osteoporos Int 28:1413\u20131422. https:\/\/doi.org\/10.1007\/s00198-016-3899-6","journal-title":"Osteoporos Int"},{"key":"7798_CR43","doi-asserted-by":"publisher","unstructured":"Birtolo MF, Rebecca Pedersini R, Andrea Palermo A, et al (2024) Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies. Eur J Endocrinol 191:117\u2013125.  https:\/\/doi.org\/10.1093\/ejendo\/lvae086","DOI":"10.1093\/ejendo\/lvae086"},{"key":"7798_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00774-024-01560-0","volume":"43","author":"S Kuba","year":"2025","unstructured":"Kuba S, Chiba K, Watanabe K et al (2025) Aromatase inhibitors, bone microstructure, and estimated bone strength in postmenopausal women with breast cancer: a 5-year prospective study. J Bone Miner Metab 43:133\u2013140. https:\/\/doi.org\/10.1007\/s00774-024-01560-0","journal-title":"J Bone Miner Metab"},{"key":"7798_CR45","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"7798_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"O Lamy","year":"2019","unstructured":"Lamy O, Stoll D, Aubry-Rozier B et al (2019) Stopping denosumab. Curr Osteoporos Rep 17:8\u201315. https:\/\/doi.org\/10.1007\/s11914-019-00502-4","journal-title":"Curr Osteoporos Rep"},{"key":"7798_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2011.06.020","volume":"48","author":"R Wolters","year":"2012","unstructured":"Wolters R, Regierer AC, Schwentner L et al (2012) A comparison of international breast cancer guidelines \u2013 do the national guidelines differ in treatment recommendations? Eur J Cancer 48:1\u201311. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.020","journal-title":"Eur J Cancer"},{"key":"7798_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"7798_CR49","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00198-023-06683-0","volume":"34","author":"B Mugnier","year":"2023","unstructured":"Mugnier B, Goncalves A, Daumas A et al (2023) Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer. Osteoporos Int 34(4):703\u2013711. https:\/\/doi.org\/10.1007\/s00198-023-06683-0","journal-title":"Osteoporos Int"},{"key":"7798_CR50","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875\u201382. https:\/\/doi.org\/10.1200\/JCO.2008.16.3832","journal-title":"J Clin Oncol"},{"key":"7798_CR51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12282-018-0896-y","volume":"26","author":"K Nakatsukasa","year":"2019","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y et al (2019) Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non- metastatic breast cancer: 24-month results. Breast Cancer 26:106\u2013112. https:\/\/doi.org\/10.1007\/s12282-018-0896-y","journal-title":"Breast Cancer"},{"key":"7798_CR52","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00774-017-0884-x","volume":"36","author":"K Nakatsukasa","year":"2018","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y et al (2018) Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Bone Miner Metab 36:716\u2013722. https:\/\/doi.org\/10.1007\/s00774-017-0884-x","journal-title":"J Bone Miner Metab"},{"key":"7798_CR53","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00774-018-0917-0","volume":"37","author":"K Nakatsukasa","year":"2019","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y et al (2019) Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab 37:301\u2013306. https:\/\/doi.org\/10.1007\/s00774-018-0917-0","journal-title":"J Bone Miner Metab"},{"key":"7798_CR54","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00223-022-01011-w","volume":"111","author":"G Mazziotti","year":"2022","unstructured":"Mazziotti G, Pedersini R, Vena W et al (2022) Real-world effectiveness of denosumab and bisphosphonates on risk of vertebral fractures in women with breast cancer undergoing treatment with aromatase inhibitors. Calcif Tissue Int 111:466\u2013474. https:\/\/doi.org\/10.1007\/s00223-022-01011-w","journal-title":"Calcif Tissue Int"},{"key":"7798_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-020-05640-3","volume":"181","author":"H Miyashita","year":"2020","unstructured":"Miyashita H, Satoi S, Kuno T et al (2020) Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat 181:279\u2013289. https:\/\/doi.org\/10.1007\/s10549-020-05640-3","journal-title":"Breast Cancer Res Treat"},{"key":"7798_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154962","volume":"128","author":"A Bassatne","year":"2022","unstructured":"Bassatne A, Bou Khalil A, Chakhtoura M et al (2022) Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Metabolism 128:154962. https:\/\/doi.org\/10.1016\/j.metabol.2021.154962","journal-title":"Metabolism"},{"key":"7798_CR57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02309","volume":"2","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK, Ghasem-Zadeh A, Hoermann R (2024) Denosumab prevents bone loss and microarchitectural deterioration in premenopausal women with breast cancer receiving estradiol suppression therapy: a randomized controlled trial. J Clin Endocrinol Metab J Clin Oncol 2:JCO2302309. https:\/\/doi.org\/10.1200\/JCO.23.02309","journal-title":"J Clin Endocrinol Metab J Clin Oncol"},{"key":"7798_CR58","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s11739-024-03725-1","volume":"19","author":"A Casabella","year":"2024","unstructured":"Casabella A, Paladin F, Bighin C et al (2024) Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK\/RANKL system\u2019s inhibitor denosumab vs. bisphosphonates. Intern Emerg Med 19:2193\u20132199. https:\/\/doi.org\/10.1007\/s11739-024-03725-1","journal-title":"Intern Emerg Med"},{"key":"7798_CR59","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40618-023-02174-5","volume":"47","author":"S Antonini","year":"2024","unstructured":"Antonini S, Pedersini R, Birtolo MF et al (2024) Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors. J Endocrinol Invest 47:433\u2013442. https:\/\/doi.org\/10.1007\/s40618-023-02174-5","journal-title":"J Endocrinol Invest"},{"key":"7798_CR60","doi-asserted-by":"publisher","unstructured":"Gianfelice C, Firmani F, Salvio G, et al (2025) Comparison Between Alendronate and Denosumab in Preventing Bone Loss and Lowering Fracture Risk Related to Adjuvant Endocrine Therapy for Breast Cancer: Real-World Data From a Third-Level Center Experience. Endocr Pract 11:S1530-891X(25)00962-0. https:\/\/doi.org\/10.1016\/j.eprac.2025.07.004","DOI":"10.1016\/j.eprac.2025.07.004"},{"issue":"7","key":"7798_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013451.pub2","volume":"2024","author":"A Adams","year":"2024","unstructured":"Adams A, Jakob T, Huth A et al (2024) Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. Cochrane Database Syst Rev (7):CD013451. https:\/\/doi.org\/10.1002\/14651858.CD013451.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"7798_CR62","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19:307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"key":"7798_CR63","doi-asserted-by":"publisher","unstructured":"Fontalis A, Gossiel F, Schini M et al (2020) The effect of denosumab treatment on osteoclast precursor cells in postmenopausal osteoporosis. Bone Rep 13:100457. https:\/\/doi.org\/10.1016\/j.bone.2016.08.01","DOI":"10.1016\/j.bone.2016.08.01"},{"key":"7798_CR64","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"2021","author":"MM McDonald","year":"2021","unstructured":"McDonald MM, Khoo WH, Ng PY et al (2021) Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 2021:1330-1347.e13. https:\/\/doi.org\/10.1016\/j.cell.2021.02.002","journal-title":"Cell"},{"key":"7798_CR65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/jbmr\/zjaf007","volume":"40","author":"SK Ramchand","year":"2025","unstructured":"Ramchand SK, McDonald MM (2025) Mechanisms to explain the overshoot in bone remodeling markers after denosumab discontinuation: are we there yet? J Bone Miner Res 40:299\u2013300. https:\/\/doi.org\/10.1093\/jbmr\/zjaf007","journal-title":"J Bone Miner Res"},{"key":"7798_CR66","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jbmr\/zjae170","volume":"40","author":"M Schini","year":"2025","unstructured":"Schini M, Gossiel F, Saini T et al (2025) The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation. J Bone Miner Res 40:301\u2013306. https:\/\/doi.org\/10.1093\/jbmr\/zjae170","journal-title":"J Bone Miner Res"},{"key":"7798_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167790","volume":"8","author":"Q Fu","year":"2023","unstructured":"Fu Q, Bustamante-Gomez NC, Reyes-Pardo H et al (2023) Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight 8:e167790. https:\/\/doi.org\/10.1172\/jci.insight.167790","journal-title":"JCI Insight"},{"key":"7798_CR68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-023-06931-3","volume":"35","author":"P Makras","year":"2024","unstructured":"Makras P, Yavropoulou MP, Polyzos et al (2024) The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection. Osteoporos Int 35:365\u2013370. https:\/\/doi.org\/10.1007\/s00198-023-06931-3","journal-title":"Osteoporos Int"},{"key":"7798_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108052","volume":"32","author":"KM Cawley","year":"2020","unstructured":"Cawley KM, Bustamante-Gomez NC, Guha AG et al (2020) Local production of osteoprotegerin by osteoblasts suppresses bone resorption. Cell Rep 32:108052. https:\/\/doi.org\/10.1016\/j.celrep.2020.108052","journal-title":"Cell Rep"},{"key":"7798_CR70","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2019.03.019","volume":"123","author":"A Fassio","year":"2019","unstructured":"Fassio A, Adami G, Benini C et al (2019) Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone 123:191\u2013195. https:\/\/doi.org\/10.1016\/j.bone.2019.03.019","journal-title":"Bone"},{"key":"7798_CR71","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/jbmr.2112","volume":"29","author":"V Rinotas","year":"2014","unstructured":"Rinotas V, Niti A, Dacquin R et al (2014) Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice. J Bone Miner Res 29:1158\u201369. https:\/\/doi.org\/10.1002\/jbmr.2112","journal-title":"J Bone Miner Res"},{"key":"7798_CR72","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P et al (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677\u2013683. https:\/\/doi.org\/10.1530\/EJE-16-1027","journal-title":"Eur J Endocrinol"},{"key":"7798_CR73","doi-asserted-by":"publisher","unstructured":"J\u00e4hn-Rickert K, W\u00f6lfel EM, Jobke B et al (2020) Elevated bone hardness under denosumab treatment, with persisting lower osteocyte viability during discontinuation. Front Endocrinol (Lausanne) 15:11\u2013250. https:\/\/doi.org\/10.3389\/fendo.2020.00250","DOI":"10.3389\/fendo.2020.00250"},{"key":"7798_CR74","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nm.2452","volume":"17","author":"T Nakashima","year":"2011","unstructured":"Nakashima T, Hayashi M, Fukunaga T et al (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231\u20131234. https:\/\/doi.org\/10.1038\/nm.2452","journal-title":"Nat Med"},{"key":"7798_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.635056","volume":"9","author":"J Mart\u00ednez-Reina","year":"2021","unstructured":"Mart\u00ednez-Reina J, Calvo-Gallego JL, Pivonka P (2021) Combined effects of exercise and denosumab treatment on local failure in post-menopausal osteoporosis-insights from bone remodelling simulations accounting for mineralisation and damage. Front Bioeng Biotechnol 9:635056. https:\/\/doi.org\/10.3389\/fbioe.2021.635056","journal-title":"Front Bioeng Biotechnol"},{"key":"7798_CR76","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00223-016-0124-8","volume":"99","author":"N Bonnet","year":"2016","unstructured":"Bonnet N, Gerbaix M, Ominsky M et al (2016) Influence of fatigue loading and bone turnover on bone strength and pattern of experimental fractures of the tibia in mice. Calcif Tissue Int 99:99\u2013109. https:\/\/doi.org\/10.1007\/s00223-016-0124-8","journal-title":"Calcif Tissue Int"},{"key":"7798_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ar.1092190104","volume":"219","author":"HM Frost","year":"1987","unstructured":"Frost HM (1987) Bone \u201cmass\u201d and the \u201cmechanostat\u201d: a proposal. Anat Rec 219:1\u20139. https:\/\/doi.org\/10.1002\/ar.1092190104","journal-title":"Anat Rec"},{"key":"7798_CR78","first-page":"114","volume":"17","author":"NH Hart","year":"2017","unstructured":"Hart NH, Nimphius S, Rantalainen T et al (2017) Mechanical basis of bone strength: influence of bone material, bone structure and muscle action. J Musculoskelet Neuronal Interact 17:114\u2013139","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"7798_CR79","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00198-025-07538-6","volume":"36","author":"P Makras","year":"2025","unstructured":"Makras P, Yavropoulou MP, Anastasilakis AD et al (2025) No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial. Osteoporos Int 36:1231\u20131237. https:\/\/doi.org\/10.1007\/s00198-025-07538-6","journal-title":"Osteoporos Int"},{"key":"7798_CR80","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"MB Zanchetta","year":"2018","unstructured":"Zanchetta MB, Boailchuk J, Massari F et al (2018) Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int 29:41\u201347. https:\/\/doi.org\/10.1007\/s00198-017-4242-6","journal-title":"Osteoporos Int"},{"key":"7798_CR81","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","volume":"103","author":"AW Popp","year":"2018","unstructured":"Popp AW, Varathan N, Buffat H et al (2018) Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int 103:50\u201354. https:\/\/doi.org\/10.1007\/s00223-018-0394-4","journal-title":"Calcif Tissue Int"},{"key":"7798_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP et al (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10:152. https:\/\/doi.org\/10.3390\/jcm10010152","journal-title":"J Clin Med"},{"key":"7798_CR83","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","volume":"30","author":"O Lamy","year":"2019","unstructured":"Lamy O, Fernandez-Fernandez E, Monjo-Henry I et al (2019) Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in pre- venting the risk of spontaneous multiple vertebral fractures: two case reports. Osteoporos Int 30:1111\u20131115. https:\/\/doi.org\/10.1007\/s00198-018-04820-8","journal-title":"Osteoporos Int"},{"key":"7798_CR84","doi-asserted-by":"publisher","unstructured":"Aubry-Rozier B, Stoll D, Gonzalez Rodriguez E et al (2017) Severe spontaneous vertebral fractures after denosumab discontinuation: 3 cases reports. J Clin Endocrinol Metab 102: 354\u2013358. https:\/\/doi.org\/10.1210\/jc.2016-3170","DOI":"10.1210\/jc.2016-3170"},{"key":"7798_CR85","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D et al (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102:354\u2013358. https:\/\/doi.org\/10.1210\/jc.2016-3170","journal-title":"J Clin Endocrinol Metab"},{"key":"7798_CR86","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","volume":"103","author":"L Tripto-Shkolnik","year":"2018","unstructured":"Tripto-Shkolnik L, Rouach V, Marcus Y et al (2018) Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int 103:44\u201349. https:\/\/doi.org\/10.1007\/s00223-018-0389-1","journal-title":"Calcif Tissue Int"},{"key":"7798_CR87","first-page":"81","volume":"14","author":"F Livio","year":"2018","unstructured":"Livio F (2018) Pharmacovigilance update. Rev Med Suisse 14:81\u201384","journal-title":"Rev Med Suisse"},{"key":"7798_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115830","volume":"144","author":"J Everts-Graber","year":"2021","unstructured":"Everts-Graber J, Reichenbach S, Gahl B et al (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone 144:115830. https:\/\/doi.org\/10.1016\/j.bone.2020.115830","journal-title":"Bone"},{"key":"7798_CR89","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"7798_CR90","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE et al (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155\u2013e4162. https:\/\/doi.org\/10.1210\/clinem\/dgab321","journal-title":"J Clin Endocrinol Metab"},{"key":"7798_CR91","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5432751","author":"E Gonzalez-Rodriguez","year":"2018","unstructured":"Gonzalez-Rodriguez E, Stoll D, Lamy O (2018) Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation. Case Rep Rheumatol. https:\/\/doi.org\/10.1155\/2018\/5432751","journal-title":"Case Rep Rheumatol"},{"key":"7798_CR92","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P et al (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296. https:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"7798_CR93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1556331621995846","volume":"17","author":"M Yeung","year":"2021","unstructured":"Yeung M, Ho K, Fornier MN et al (2021) Vertebral fractures after denosumab discontinuation in breast cancer survivors: a single institution experience. HSS J 17:185\u2013191. https:\/\/doi.org\/10.1177\/1556331621995846","journal-title":"HSS J"},{"key":"7798_CR94","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C et al (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37:2916\u20132946. https:\/\/doi.org\/10.1200\/JCO.19.01696","journal-title":"J Clin Oncol"},{"key":"7798_CR95","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","volume":"21","author":"AS S\u00f8lling","year":"2023","unstructured":"S\u00f8lling AS, Tsourdi E, Harsl\u00f8f T et al (2023) Denosumab discontinuation. Curr Osteoporos Rep 21:95\u2013103. https:\/\/doi.org\/10.1007\/s11914-022-00771-6","journal-title":"Curr Osteoporos Rep"},{"key":"7798_CR96","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, cross-over comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u201326. https:\/\/doi.org\/10.1007\/s00198-011-1780-1","journal-title":"Osteoporos Int"},{"key":"7798_CR97","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz095","volume":"105","author":"D Kendler","year":"2020","unstructured":"Kendler D, Chines A, Clark P et al (2020) Bone mineral density after transitioning from denosumab to alendronate. J Clin Endocrinol Metab 105:e255\u2013e264. https:\/\/doi.org\/10.1210\/clinem\/dgz095","journal-title":"J Clin Endocrinol Metab"},{"key":"7798_CR98","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","volume":"38","author":"H Kondo","year":"2020","unstructured":"Kondo H, Okimoto N, Yoshioka T et al (2020) Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. J Bone Miner Metab 38:894\u2013902. https:\/\/doi.org\/10.1007\/s00774-020-01126-w","journal-title":"J Bone Miner Metab"},{"key":"7798_CR99","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/jbmr.4259","volume":"36","author":"SK Ramchand","year":"2021","unstructured":"Ramchand SK, David NL, Lee H et al (2021) Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD study extension. J Bone Miner Res 36:921\u2013930. https:\/\/doi.org\/10.1002\/jbmr.4259","journal-title":"J Bone Miner Res"},{"key":"7798_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115478","volume":"138","author":"P Makras","year":"2020","unstructured":"Makras P, Papapoulos SE, Polyzos SA et al (2020) The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone 138:115478. https:\/\/doi.org\/10.1016\/j.bone.2020.115478","journal-title":"Bone"},{"key":"7798_CR101","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","volume":"35","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK, Tsai JN, Lee H et al (2024) The comparison of alendronate and raloxifene after denosumab (CARD) study: a comparative efficacy trial. Osteoporos Int 35:255\u2013263. https:\/\/doi.org\/10.1007\/s00198-023-06932-2","journal-title":"Osteoporos Int"},{"key":"7798_CR102","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B et al (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101:371\u2013374. https:\/\/doi.org\/10.1007\/s00223-017-0288-x","journal-title":"Calcif Tissue Int"},{"key":"7798_CR103","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35:1858\u20131870. https:\/\/doi.org\/10.1002\/jbmr.4098","journal-title":"J Bone Miner Res"},{"key":"7798_CR104","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36:1245\u20131254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Miner Res"},{"key":"7798_CR105","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR et al (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res 35:1207\u20131215. https:\/\/doi.org\/10.1002\/jbmr.3962","journal-title":"J Bone Miner Res"},{"key":"7798_CR106","doi-asserted-by":"publisher","unstructured":"Everts-Graber J, Reichenbach S, Gahl B et al (2020) Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting. Bone Miner Res 35:1207\u20131215. https:\/\/doi.org\/10.1016\/j.bone.2022.116498","DOI":"10.1016\/j.bone.2022.116498"},{"key":"7798_CR107","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ejendo\/lvaf013","volume":"192","author":"KH Lu","year":"2025","unstructured":"Lu KH, Wang SI, Yang SF (2025) Denosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate. J Endocrinol 192:180\u2013190. https:\/\/doi.org\/10.1093\/ejendo\/lvaf013","journal-title":"J Endocrinol"},{"key":"7798_CR108","first-page":"S114","volume":"S1","author":"MB Zanchetta","year":"2019","unstructured":"Zanchetta MB, Pelegrin C, Silveira F et al (2019) Bisphosphonates prevent bone loss associated with denosumab discontinuation. J Bone Miner Res S1:S114\u2013S115","journal-title":"J Bone Miner Res"},{"key":"7798_CR109","first-page":"S259","volume":"1","author":"K Ebina","year":"2019","unstructured":"Ebina K, Miyama A, Hirao M et al (2019) Assessment of the effects of sequential treatment after discontinuing denosumab in 64 patients with postmenopausal osteoporosis. J Bone Miner Res S 1:S259","journal-title":"J Bone Miner Res S"},{"key":"7798_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100290","volume":"13","author":"M Laroche","year":"2020","unstructured":"Laroche M, Couture G, Ruyssen-Witrand A et al (2020) Effect of risedronate on bone loss at discontinuation of denosumab. Bone Rep 13:100290. https:\/\/doi.org\/10.1016\/j.bonr.2020.100290","journal-title":"Bone Rep"},{"key":"7798_CR111","unstructured":"Dickens L, Vokes T (2019) Oral vs. intravenous bisphosphonates for preventing bone loss after denosumab discontinuation. J Bone Miner Res S1:S182"},{"key":"7798_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100290","volume":"13","author":"M Laroche","year":"2020","unstructured":"Laroche M, Couture G, Ruyssen-Witrand A et al (2020) Effect of risedronate on bone loss at discontinuation of denosumab. Bone Rep 13:100290. https:\/\/doi.org\/10.1016\/j.bonr.2020.100290","journal-title":"Bone Rep"},{"key":"7798_CR113","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.43899","volume":"7","author":"CC Lee","year":"2024","unstructured":"Lee CC, Wang CY, Yen HK et al (2024) Zoledronate sequential therapy after denosumab discontinuation to prevent bone mineral density reduction: a randomized clinical trial. JAMA Netw Open 7:e2443899. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43899","journal-title":"JAMA Netw Open"},{"key":"7798_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10731","volume":"7","author":"M Laroche","year":"2023","unstructured":"Laroche M, Couture G, Degbo\u00e9 Y (2023) Discontinuation of denosumab: gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine. JBMR Plus 7:e10731. https:\/\/doi.org\/10.1002\/jbm4.10731","journal-title":"JBMR Plus"},{"key":"7798_CR115","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P, Faouzi M, Buclin T et al (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36:1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335","journal-title":"J Bone Miner Res"},{"key":"7798_CR116","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","volume":"31","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hashimoto J, Kashii M et al (2020) Effects of follow-on therapy after denosumab discon- tinuation in patients with postmenopausal osteoporosis. Mod Rheumatol 31:485\u201392. https:\/\/doi.org\/10.1080\/14397595.2020.1769895","journal-title":"Mod Rheumatol"},{"key":"7798_CR117","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-21-0157","volume":"185","author":"G Grassi","year":"2021","unstructured":"Grassi G, Chiodini I, Palmieri S et al (2021) Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence. Eur J Endocrinol 185:387\u2013396. https:\/\/doi.org\/10.1530\/EJE-21-0157","journal-title":"Eur J Endocrinol"},{"key":"7798_CR118","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","volume":"28","author":"T Lehmann","year":"2017","unstructured":"Lehmann T, Aeberli D (2017) Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int 28:3067\u20133068. https:\/\/doi.org\/10.1007\/s00198-017-4108-y","journal-title":"Osteoporos Int"},{"key":"7798_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10396","volume":"4","author":"D Davidoff","year":"2020","unstructured":"Davidoff D, Girgis C (2020) Failure of oral risedronate therapy to prevent spontaneous vertebral fracture in a patient ceasing denosumab: a cautionary case. JBMR Plus 4:e10396. https:\/\/doi.org\/10.1002\/jbm4.10396","journal-title":"JBMR Plus"},{"key":"7798_CR120","first-page":"S183","volume":"1","author":"A Popp","year":"2019","unstructured":"Popp A, Bock B, Senn C et al (2019) Early recurrence of increased bone turnover markers after initial response to single dose zoledronate following denosumab discontinuation in postmenopausal women. J Bone Miner Res S 1:S183","journal-title":"J Bone Miner Res S"},{"key":"7798_CR121","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","volume":"109","author":"G Grassi","year":"2024","unstructured":"Grassi G, Ghielmetti A, Zampogna M et al (2024) Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion? Clin Endocrinol 109:e1817\u2013e1826. https:\/\/doi.org\/10.1210\/clinem\/dgae224","journal-title":"Clin Endocrinol"},{"key":"7798_CR122","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","volume":"80","author":"AA Khan","year":"2023","unstructured":"Khan AA, AbuAlrob H, M\u2019Hiri I et al (2023) Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study. Endocrine 80:647\u2013657. https:\/\/doi.org\/10.1007\/s12020-022-03230-5","journal-title":"Endocrine"},{"key":"7798_CR123","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/EJE-17-0585","volume":"178","author":"R Eastell","year":"2018","unstructured":"Eastell R, Pigott T, Gossiel F et al (2018) Diagnosis of endocrine disease: bone turnover markers: are they clinically useful? Eur J Endocrinol 178:R19\u2013R31. https:\/\/doi.org\/10.1530\/EJE-17-0585","journal-title":"Eur J Endocrinol"},{"key":"7798_CR124","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s00198-014-2787-1","volume":"25","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, McCloskey E, Branco J et al (2014) Goal-directed treatment of osteoporosis in Europe. Osteoporos Int 25:2533\u20132543. https:\/\/doi.org\/10.1007\/s00198-014-2787-1","journal-title":"Osteoporos Int"},{"key":"7798_CR125","doi-asserted-by":"publisher","unstructured":"Cl\u00e9zardin P, Coleman R, Puppo M et al (2021) Bone metastasis: mechanisms, therapies, and biomarkers. Phys Physiol Rev 101:97\u2013855.  https:\/\/doi.org\/10.1152\/physrev.00012.2019","DOI":"10.1152\/physrev.00012.2019"},{"key":"7798_CR126","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","volume":"20","author":"AA Khan","year":"2017","unstructured":"Khan AA, Morrison A, Kendler DL et al (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom 20:8\u201324. https:\/\/doi.org\/10.1016\/j.jocd.2016.09.005","journal-title":"J Clin Densitom"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07798-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07798-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07798-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:03:47Z","timestamp":1772582627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07798-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7798"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07798-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"E.B. reports advisory and lecture fees from Amgen. A.E. M Abdellah El Maghraoui has received lecture fees from Amgen. C.Ca. has received advisory and lecture fees from FAES farrma, Novartis, Adium, Tecnofarma. J. C.-A. reports advisory board and lecture fees from Mabxience & SPA Farma Ib\u00e9rica. C. Co. reports congress and lecture fees from Amgen and has received a research grant from Amgen and the 2022 French Amgen Research Award. T. de V. reports advisory and lecture fees from Abbott, Amgen and Cipla Medpro. P. H. has received lecture fees from Amgen, Astellos, Besins, Exeltis, Fresenius, Gedeon Richter, Hexal, Novartis, Pfizer, Stada, Theramex, and UCB. A. E. M. has received lecture fees from Amgen. M.L.B. has received fee for honoraria from Amgen, Ascendis, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, for Grants and\/or speaker from Alexion, Amgen, Amolyt, Bruno Farmaceutici, CoGeDi, Echolight, Gedeon Richter, Kyowa Kirin, Monte Rosa Therapeutics, UCB and for Consultant from Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Enterabio, Kyowa Kirin, Personal Genomics, and Septerna. J. J. B., P. E., D. K., G.M, N. N. P.V., and R. R. declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}